Member Posts > Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): A Novel Cannabidiol Therapy for Advanced Heart Failure
The Next Step in Heart Failure Treatment
Heart failure is a progressive condition that affects millions worldwide. CRD-38 is a subcutaneous cannabidiol formulation designed to target cardiac inflammation and structural remodeling, two major contributors to heart failure progression.
Why CRD-38?
✔ Higher bioavailability, ensuring better absorption.
✔ Stable plasma drug levels, improving treatment consistency.
✔ Less frequent dosing, making it easier for patients to follow.
Preclinical Data Highlights
📌 Reduced BNP levels, indicating improved cardiac function.
📌 Lower cardiac fat deposits, minimizing stress on the heart.
📌 Confirmed anti-inflammatory effects, demonstrating CRD-38's potential as a disease-modifying therapy.
Advancing CRD-38 Toward Clinical Trials
CRD-38 is currently in Investigational New Drug (IND)-enabling studies, focusing on:
✔ Pharmacokinetic optimization.
✔ Preclinical safety evaluation.
✔ Regulatory preparations for human trials.
🔗 Stay Updated on CRD-38's Progress:

#CardiolTherapeutics #HeartHealth #MedicalInnovation #CardiacCare #PatientStories #Myocarditis #Pericarditis #HealthcareResearch #CommunityEngagement #CannabidiolResearch #HeartDiseaseAwareness #AdvancedTherapies #CardiolRx #CRD38